Related Experiment Video
Updated: Nov 23, 2025

Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
Treating Autism With Bumetanide: Are Large Multicentric and Monocentric Trials on Selected Populations Complementary?
Eric Lemonnier1, Hamed Rabiei2, David Makowski3
1Autism Expert Center and Autism Resource Center of Limousin, University Hospital Center, Limoges, France.
Abstract:
In their article in the Journal, Sprengers et al.1 conclude that bumetanide does not attenuate autism spectrum disorder (ASD) despite a nominally significant treatment effect in repetitive behaviors, which is a core symptom of ASD but was defined as a secondary measure in this trial. Four earlier studies performed by 3 independent institutes, including 2 studies2,3 not mentioned by Sprengers et al., testing a total of 169 children (versus 122 placebo) showed a significant amelioration of ASD symptoms. Bumetanide also significantly attenuated behavioral features of patients with tuberous sclerosis according to another study by Sprengers' same group.4.
Related Concept Videos
Autism Spectrum Disorder
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
Clinical Trials: Overview
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Bioequivalence studies: Biowaivers

